Matt Hoffman

The BLA was originally accepted by the FDA for review in September 2017, with the product intended to be used for the treatment of immunological conditions such as rheumatoid arthritis, as well as blood cancers.

While its safety profile was lessened, celecoxib, in comparison with naproxen and ibuprofen, remained favorable when taken with aspirin.

Previously approved for moderate-to-severe rheumatoid arthritis, golimumab received 2 new indications.

Improvement in DAS28 scores was statistically significant in 26% of patients using adalimumab every 3 weeks compared to every 2 weeks.